Nrx Pharmaceuticals Stock Earnings Reports

NRx reported a productive Q1 2026 with material progress across its pipeline and operations. Key commercial focus is KETAFREE, a preservative-free, U.S.-manufactured intravenous ketamine product advancing through final FDA review with anticipated summer 2026 timing; the company has initiated commercial manufacturing using blow-fill-seal (BFS) technology and expects scalable capacity (targeting multi-hundred-thousand to million-unit inventory at launch) to address ongoing national shortages and the underserved ketamine clinic market. For neuropsychiatric programs, the NRX-100 NDA is on track for second-quarter submission and will combine >1,000 clinical trial patients plus real-world evidence from ~65,000 patients; FDA discussions have been positive about using RWE and a broader depression indication that includes suicidality. NRX-101 progressed with Module 3 filed and received FDA clearance to start the MIND1 Phase IIb/III trial (400 patients) as an adjunct to accelerated TMS, targeting a >$1B opportunity and pursuing nondilutive funding and military/academic partnerships. HOPE Therapeutics clinic network is expanding (5 clinics in Q1, targeting 8+ by end of Q2) and integrating digital tools (EMOBOT) and TMS partnerships. The company acquired Geneuro assets to create a new anti-HERV platform for neurological/autoimmune indications. Financially, NRx reduced net loss by 74% YoY to $1.4M for the quarter, had $6.7M cash at 3/31/26 (management expects runway into 2026), and raised ~$7M post-quarter via its ATM program; operating losses increased due to strategic investments in commercial readiness and pipeline advancement.